Khadija Hamisi, NP
Psychiatric/Mental Health · Colton, CANPI 1225360498
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Alkermes, Inc. at 33.5% of the total. Reporting peaked in 2021 at $5,729 and has fallen 51.9% since, to $2,755 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $36.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$5K
- Teva Pharmaceuticals USA, Inc.$4K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Bausch Health US, LLC$1K
- Otsuka America Pharmaceutical, Inc.$967
- Johnson & Johnson$525
- plus $2K from 10 others
Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$3K
What the payments were for
- Consulting fees$2,44816%
- Speaking & faculty fees$5,28534%
- Food & beverage$7,49748%
- Education$2462%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 145 | $5,183 |
| Teva Pharmaceuticals USA, Inc. | 47 | $3,877 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $1,888 |
| Bausch Health US, LLC | 63 | $1,306 |
| Otsuka America Pharmaceutical, Inc. | 53 | $967 |
| Johnson & Johnson | 26 | $525 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $416 |
| AbbVie | 13 | $297 |
| E.r. Squibb & Sons, L.L.C. | 14 | $263 |
| Neurocrine Biosciences, Inc. | 4 | $231 |
| Lundbeck LLC | 9 | $159 |
| Sunovion Pharmaceuticals Inc. | 9 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $105 |
| Vanda Pharmaceuticals Inc. | 3 | $78 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Noven Therapeutics, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$10,609
- AUSTEDO$2,900
- ARISTADA INITIO$2,652
- ABILIFY ASIMTUFII$1,888
- VIVITROL$400
- INGREZZA$166
How this compares
$15,476 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify AsimtufiiAripiprazole | 17 | $94,001 |
| Aripiprazole | 126 | $10,963 |
| TrintellixVortioxetine Hydrobromide | 16 | $10,814 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,461 |
| Atomoxetine Hcl | 28 | $3,257 |
| Quetiapine Fumarate | 125 | $1,338 |
| Trazodone Hcl | 104 | $1,337 |
| Olanzapine | 119 | $1,207 |
| Bupropion XlBupropion Hcl | 85 | $1,098 |
| Risperidone | 40 | $998 |
| Buprenorphine Hcl | 12 | $959 |
| Buspirone Hcl | 73 | $951 |
| Doxepin Hcl | 13 | $911 |
| Mirtazapine | 80 | $897 |
| Hydroxyzine Hcl | 48 | $788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $967 | $94,00117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $105 | $15,27628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Colton
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.